Opaleye Management Inc. Edgewise Therapeutics, Inc. Transaction History

Opaleye Management Inc.

$390 Million
Q2 2024

A detailed history of Opaleye Management Inc. transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 580,000 shares of EWTX stock, worth $10.2 Million. This represents 2.68% of its overall portfolio holdings.

Number of Shares

580,000

Previous 665,000 12.78%

Holding current value

$10.2 Million

Previous $12.1 Million 13.88%

% of portfolio

2.68%

Previous 2.95%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$15.08 - $21.23 $1.28 Million - $1.8 Million	-85,000 Reduced 12.78%	580,000 $10.4 Million
Q1 2024 May 15, 2024	SELL	$9.25 - $19.97 $314,500 - $678,980	-34,000 Reduced 4.86%	665,000 $12.1 Million
Q4 2023 Feb 14, 2024	SELL	$5.51 - $12.1 $971,991 - $2.13 Million	-176,405 Reduced 20.15%	699,000 $7.65 Million
Q3 2023 Nov 14, 2023	BUY	$5.73 - $7.69 $346,120 - $464,514	60,405 Added 7.41%	875,405 $5.02 Million
Q2 2023 Aug 14, 2023	BUY	$5.71 - $10.29 $371,150 - $668,850	65,000 Added 8.67%	815,000 $6.32 Million
Q1 2023 May 12, 2023	BUY	$6.66 - $11.33 $923,076 - $1.57 Million	138,600 Added 22.67%	750,000 $5 Million
Q4 2022 Feb 10, 2023	SELL	$7.58 - $11.08 $178,888 - $261,488	-23,600 Reduced 3.72%	611,400 $5.47 Million
Q3 2022 Nov 14, 2022	BUY	$8.08 - $13.58 $1.48 Million - $2.49 Million	183,600 Added 40.67%	635,000 $6.25 Million
Q2 2022 Aug 15, 2022	BUY	$5.67 - $9.87 $841,428 - $1.46 Million	148,400 Added 48.98%	451,400 $3.59 Million
Q1 2022 May 16, 2022	BUY	$9.1 - $18.97 $2.76 Million - $5.75 Million	303,000 New	303,000 $2.94 Million

Others Institutions Holding EWTX

# of Institutions

144

Shares Held

96.7M

Call Options Held

45.7K

Put Options Held

5.3K

View Full List

About Edgewise Therapeutics, Inc.

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.11B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

More about EWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.

Account

Opaleye Management Inc. Edgewise Therapeutics, Inc. Transaction History